. . . . "11394"^^ . . "21008987"^^ . "Jonathan W. Simons is an American physician-scientist, medical oncologist, and leader in prostate cancer research. In August 2021, Simons was appointed the Medical Director and Chief Science Officer of the Marcus Foundation. Prior to joining the Marcus Foundation, he served a 14-year tenure as the President and chief executive officer of the Prostate Cancer Foundation. Simons\u2019 laboratories, partly funded by the Prostate Cancer Foundation, at Johns Hopkins University and Emory University made original contributions to understanding the molecular biology of prostate cancer metastasis and principles of \u201Cbroken immune tolerance\u201D via T cell based immunotherapy for prostate cancer. The Simons lab invented GM-CSF genetically engineered vaccines for prostate cancer in rodents and humans for these"@en . . . . . "1124653972"^^ . . . . . . . . . . . . "Jonathan W. Simons"@en . . . "Jonathan W. Simons"@en . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "Washington, D.C., U.S."@en . "Jonathan Simons"@en . . . . . . . "Jonathan W. Simons is an American physician-scientist, medical oncologist, and leader in prostate cancer research. In August 2021, Simons was appointed the Medical Director and Chief Science Officer of the Marcus Foundation. Prior to joining the Marcus Foundation, he served a 14-year tenure as the President and chief executive officer of the Prostate Cancer Foundation. Simons\u2019 laboratories, partly funded by the Prostate Cancer Foundation, at Johns Hopkins University and Emory University made original contributions to understanding the molecular biology of prostate cancer metastasis and principles of \u201Cbroken immune tolerance\u201D via T cell based immunotherapy for prostate cancer. The Simons lab invented GM-CSF genetically engineered vaccines for prostate cancer in rodents and humans for these studies, and subsequently Simons\u2019 clinical team took the biotechnology into the world\u2019s first human gene therapy clinical trials for advanced prostate cancer at Johns Hopkins."@en . . . . . . . . . . . . . . . . . . . . . . . . . .